Phase 1 and Phase 2 Clinical Trials of Cancer Chemopreventive Agents
Phase 1 and Phase 2 Clinical Trials of Cancer Chemopreventive Agents
批准号:
8339913
负责人:
POWELL BROWN
金额:
$168.17万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-09-30 至 2014-09-29
关键词:
BiologicalBiological MarkersChemopreventionChemopreventive AgentChronicClinicalClinical ResearchClinical TrialsContractsDivision of Cancer PreventionDoseDrug KineticsInstitutionIntraepithelial NeoplasiaMalignant NeoplasmsMolecular TargetNational Cancer InstitutePhasePhase I Clinical TrialsPhase II Clinical TrialsPreventiveResearch InfrastructureSafetyToxic effectTranslational Researchcancer preventioncarcinogenesisclinically relevantdesigninhibitor/antagonistinsightnoveltriple-negative invasive breast carcinoma
中文摘要
此次采购的目的是进行国家癌症研究所(NCI)癌症预防部(DCP)赞助的癌症预防药物的多项早期(1期和2期)临床试验,并建立由一个或多个合作机构组成的基础设施,以进行这些试验。这些试验将通过评估这些药物对分子靶点的生物学作用和确定临床相关性来评估各种药物的癌症预防潜力。
英文摘要
The purpose of this procurement is to conduct multiple early phase (Phase 1 and Phase 2) clinical trials of the National Cancer Institute (NCI), Division of Cancer Prevention (DCP)-sponsored cancer preventive agents and to establish the infrastructures composed of one or more collaborating institutions that will perform these trials. The trials will assess the cancer preventive potential of various agents by evaluating the biologic effects of these agents on their molecular targets and by determining clinically relevant correlates.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TARGETING STAT3 TO PREVENT NON-SMALL CELL LUNG CANCER (NSCLC) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
-
批准号:10705395
-
项目类别:
-
资助金额:$109.8万
-
财政年份:2022
-
负责人:POWELL BROWN
-
依托单位:
OPTIMIZATION OF DOSING REGIMENS OF SULINDAC IN COMBINATION WITH ERLOTINIB FOR SMALL INTESTINAL AND COLON CANCER PREVENTION
-
批准号:10020546
-
项目类别:
-
资助金额:$85.43万
-
财政年份:2019
-
负责人:POWELL BROWN
-
依托单位:
CORE INFRASTRUCTURE SUPPORT
-
批准号:8948577
-
项目类别:
-
资助金额:$79.33万
-
财政年份:2014
-
负责人:POWELL BROWN
-
依托单位:
海外基金